Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Aggressive peripheral T-cell lymphomas (specified and unspecified types).

Kerry J Savage1

  • 1British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver BC V5Z 4E6, Canada. ksavage@bccancer.bc.ca

Hematology. American Society of Hematology. Education Program
|November 24, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patterns.

Haematologica·2026
Same author

High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

LySeqST: a targeted sequencing assay for robust genomic classification of diffuse large B-cell lymphoma.

Blood advances·2026
Same author

Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses.

Blood advances·2026
Same author

IL1RAP antibody-drug conjugates potently target primary and metastatic disease in multiple oncofusion-driven cancers.

Cancer discovery·2026
Same author

Bleomycin omission in limited-stage classic Hodgkin lymphoma with negative PET scan after two cycles of ABVD.

Haematologica·2026
Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025
Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025
Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025
Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025
See all related articles

Peripheral T-cell lymphomas (PTCLs) are rare, diverse cancers with poor prognosis, except for ALK-positive anaplastic large-cell lymphoma (ALK-pos ALCL). Further research and targeted clinical trials are crucial for improved PTCL understanding and treatment.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Peripheral T-cell lymphomas (PTCLs) represent a rare and heterogeneous group of hematologic malignancies.
  • PTCLs are less understood than B-cell lymphomas, leading to poorly defined treatment strategies and poor patient outcomes.

Purpose of the Study:

  • To highlight the biological diversity and clinical heterogeneity of PTCLs.
  • To emphasize the need for further research into PTCL molecular mechanisms and therapeutic targets.

Main Methods:

  • Review of existing literature on PTCL classification, prognosis, and treatment.
  • Discussion of the role of molecular profiling in understanding PTCL heterogeneity.

Main Results:

  • Most PTCL subtypes have a poor prognosis, with a 5-year survival rate around 30%.

Related Experiment Videos

  • Anaplastic large-cell lymphoma, ALK-positive (ALK-pos ALCL) is an exception with a better outcome.
  • The International Prognostic Index aids in risk stratification for certain PTCL subtypes like PTCL-NOS.

    • Conclusions:

    • Clinical heterogeneity in PTCLs likely stems from underlying molecular differences.
    • Gene expression profiling offers potential for refining PTCL classification and identifying new therapeutic targets.
    • Dedicated clinical trials are essential to advance PTCL understanding and optimize patient management.